Skip to main content
. 2025 Feb 25;35(2):129–167. doi: 10.25259/ijn_389_23

Table 13:

Evidence profile for roxadustat as an alternative to ESA for anemia in NDD-CKD patients

Recommendation for use in research setting only This recommendation is evidence informed.
Roxadustat should not be used for NDD-CKD patients, except in the context of an approved randomized controlled trial. The panel recommends conduct of large head-to-head multicentric randomized controlled trials in the South Asian region on NDD-CKD patients and measuring critically important outcomes (as elucidated in this guideline) such that evidence base for roxadustat is improved.

ESA: Eythropoiesis-stimulating agents, NDD: Nondialysis dependent, CKD: Chronic kidney disease